top of page

EPI-CAN new generation of liquid biopsy biomarkers

EPI-CAN brings new generation of epigenetic biomarkers for clinical applications.

Science Lab

Research

Our preliminary research results are available from:

Early cancer diagnosis increases 4 times survival rate*

Early cancer diagnostic tests based on liquid biopsy concept, not only saves lives, but also bring significant reductions of the cost of cancer management in the health care systems.

*Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50-79 diagnosed 2006-2015. Data on file GA-2021-004.

What is
liquid biopsy?

A liquid biopsy is a blood-based diagnostic test that detects cancer DNA circulating in the bloodstream, referred to as “circulating tumor DNA” or more generally "cell-free DNA".

Zarodkowych komórek macierzystych

About EPI-CAN

Spin-off based on patent pending technology, developed at The Independent Clinical Epignetic Laboratory, Pomeranian Medical University in Szczecin, Poland.

Proof-of-concept

We have proofed that our solution can be used to detect and classify a cancer using liquid biopsy. Soon to be published in peer-review journal.

Milestones

Scroll to learn about our project’s journey

YEAR

2021

First grant

In 2021 we received the first grant to perform proof-of-concept of our innovation.

YEAR

2022

First liquid-biopsy test

In 2022 we successfully extracted and classify cell-free DNA samples from blood of cancer and healthy patients using our technology.

EPI-CAN TEAM

Zrzut ekranu 2023-10-03 140639.png

Jan

Bińkowski

Co-founder

thumbnail_034A2871-Edit.jpg

Tomasz K.

Wojdacz

Co-founder, PhD, MBA

bottom of page